Biofrontera Inc. (BFRI) Value Adjusted for Debt and Cash

The market trend for Biofrontera Inc. (BFRI) illustrated on this price chart demonstrates an enterprise value of 15.04. Business growth is driven by Ameluz system sales in the US, the expansion of the sales department, and improved insurance coverage. Meanwhile, the company is engaged in a fierce battle with manufacturers of affordable alternatives. This dermatological player is seeking approval for the treatment of extensive skin areas while developing specialized pharmaceuticals.

BFRI (Biofrontera, Inc.) Total Company Value history from 11/23/2025 to 10/27/2026

Biofrontera (BFRI) - metric breakdowns and financial figures

- price and consensus price forecast:

Quote Chart Biofrontera, Inc.|BFRI - Price Target Chart

- market capitalization data:

Market Value Biofrontera|BFRI - Enterprise Value

- book capitalization data:

Net Assets per Share Biofrontera|BFRI - Company Book Value|Market Capitalization to Net Assets biofrontera-us.com|BFRI - Company Total Assets

- debt and liquidity data:

All Debt to Shareholders' Equity Ratio Biofrontera Inc.|BFRI - Long-Term Debt to Capital|Short-Term Debt to Capital Biofrontera, Inc.|BFRI - Company Debts|Debt to Net Assets Ratio Biofrontera

Comprehensive company analysis:Biofrontera Inc. (BFRI)

Sales of photodynamic therapy systems and the Ameluz drug across US medical centers form the asset base of Biofrontera Inc. (BFRI), the value of which is reflected in this metric. The enterprise value assessment sums the market capitalization with net debt, allowing the investor to determine the actual buyout price of the company, accounting for all liabilities and cash reserves to analyze financial stability.

Competitor analysis for Biofrontera Inc.

Krystal Biotech Inc - Full Business Value|Total Company Value Apogee Pharma (APGE)|ARQT - Value Adjusted for Debt and Cash|Vericel Corporation - Enterprise Value|ORKA (orukatx.com) - Company Buyout Price|Total Company Value Sanara MedTech, Inc. SMTI|Full Business Value DBV Technologies SA|Solesence Inc (SLSN) - Enterprise Value|Value Adjusted for Debt and Cash journeymedicalcorp.com (DERM)|Enterprise Value FBRX (Forte Biosciences, Inc.)|empro.my - Enterprise Value|Total Company Value Sol-Gel Technologies Ltd. (SLGL)|AXIL: Value Adjusted for Debt and Cash|MDCX (Medicus Pharma Limited) - Total Company Value|Verrica Pharmaceuticals Inc. (VRCA) - Real Price to Acquire Entire Company|HOTH (Hoth Therapeutics Inc.) - Enterprise Value|Enterprise Value VYNE Therapeutics Inc (VYNE)|Sonoma Pharmaceuticals (SNOA) - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash QNRX (quoinpharma.com)|Total Company Value AZTR|Dermata Corp - Company Buyout Price|Elevai Labs Inc. - Total Company Value|RVNC - Enterprise Value